Lycia Therapeutics’ Director Buys 33,307 Zero‑Cost Options as Insider Confidence Shakes Up Market Sentiment
Lycia Therapeutics insider buying spurs confidence: 33,307 zero‑cost options signal exec optimism on LYTAC tech and a potentially undervalued IPO‑debuted stock.
3 minutes to read